Enabling faster pharmaceutical development by near atomically resolved microscopy.
About Vitroprobe
Vitroprobe Analytics develops biomolecular analysis at the atomic scale to help design new pharmaceutical drugs.
The development of new pharmaceuticals is a slow and expensive process. Successful drug design relies on an understanding of how drug candidates interact with their targets in the body. With Vitroprobe’s novel patented technique, drug targets can be examined with unmatched resolution, enabling fine-tuning of new pharmaceuticals.
The technology is the result of interdisciplinary research at Chalmers University of Technology by Vitroprobe’s founders Martin Andersson, Gustav Sundell and Mats Hulander.
Vitroprobe was founded in 2020 and is working towards speeding up development of new pharmaceuticals by providing unique information in close collaboration with academia and industry.
We are the team of Vitroprobe analytics
Martin Andersson
Professor of chemistry
Mats Hulander
Doctor of biology
Gustav Sundell
Doctor of physics
Gustav Eriksson
Doctoral student
Partners
Our partners are as important as the team itself.
With your support we are able to present out contribution.
Do you want more information or to be a part of our journey?
Write to us and we’ll get in contact with you.
Elevating Pharmaceutical Analysis with Silica Matrix and Atom Probe Tomography (APT)
Vitroprobe provides a unique method of preparing a material that embeds proteins in a silica matrix, that retains the sensitive molecules in their native state while allowing for analysis using Atom Probe Tomography (APT). Microgram quantities of the protein of interest is enough to produce a sufficient amount of material to be analyzed and obtain high quality information.
